AACR22: CodeBreaK 100 trial data shows long-term clinical benefit of sotorasib for NSCLC

The long-term outcomes from the Phase I/II global, single-arm CodeBreaK100 trial were presented at the AACR Annual Meeting 2022 (8−13 April 2022; LA, USA) and showed that patients with NSCLC, treated with the sotorasib (Lumakras™) had a 2-year overall survival rate of 32.5%. Sotorasib is a first-in-class KRASG12C inhibitor and in May 2021 was US FDA approved for use in adults with KRAS p.G12C-mutated locally advanced or metastatic NSCLC who received prior systemic therapies. This approval was based on the Phase I/II global, single-arm CodeBreaK100 trial. You may also be interested in: AACR Annual Meeting 2022: what talks should you...